This company has been acquired
Salud financiera de hoja de balance de GreenLight Biosciences Holdings
Salud financiera controles de criterios 4/6
GreenLight Biosciences Holdings has a total shareholder equity of $21.9M and total debt of $24.5M, which brings its debt-to-equity ratio to 111.6%. Its total assets and total liabilities are $113.7M and $91.8M respectively.
Información clave
111.6%
Ratio deuda-patrimonio
US$24.48m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$32.35m |
| Patrimonio | US$21.94m |
| Total pasivo | US$91.75m |
| Activos totales | US$113.69m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Análisis de la situación financiera
Pasivos a corto plazo: GRNA's short term assets ($37.7M) exceed its short term liabilities ($31.2M).
Pasivo a largo plazo: GRNA's short term assets ($37.7M) do not cover its long term liabilities ($60.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: GRNA has more cash than its total debt.
Reducción de la deuda: Insufficient data to determine if GRNA's debt to equity ratio has reduced over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: GRNA has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Pronóstico de cash runway: GRNA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.